SCH 58261: A selective A(2A) adenosine receptor antagonist

Drug Development Research

Volumn 42, Issue 2, 1997, Pages 63-70

  Ongini, Ennio ^a,b  

^a Schering Plough Research Institute   (Italy)

^b Schering Plough Research Institute   (Italy)

Author keywords

A(2A) adenosine receptor antagonists; A(2A) adenosine receptors; Parkinson's disease; SCH 58261; Stroke

Indexed keywords

5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 9 CHLORO 2 (2 FURYL) 5,6 DIHYDRO 5 IMINO 1,2,4 TRIAZOLO[2,3 C]QUINAZOLINE; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A2 RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; CAFFEINE; CYCLIC AMP; LEVODOPA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE; BRAIN INJURY; BRAIN PROTECTION; CATTLE; CONCENTRATION RESPONSE; DRUG ACTIVITY; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; LOCOMOTION; MOUSE; NONHUMAN; PARKINSON DISEASE; PHARMACOLOGY; RAT; SIGNAL TRANSDUCTION; STROKE; VASODILATATION; WAKEFULNESS;

EID: 0031432929     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(199710)42:2<63::AID-DDR2>3.0.CO;2-N     Document Type: Article

References (46)

1. Alexander SPH, Peters JA (eds) (1997) Receptor and ion channel nomenclature supplement. Trends Pharmacol Sci 18:7-8.
2. 2B4) cells. Br J Pharmacol 119:1286-1290.
3. 2A adenosine receptor antagonists. Bioorg Med Chem Lett 4:2539-2544.
4. 2A adenosine receptor antagonists. Current Med Chem 2:707-722.
5. 2A adenosine antagonists. J Med Chem 39:1164-1171.
6. 3H]SCH 58261 to coronary atery membranes. Circ Res 79:1153-1160.
7. 2A adenosine receptor mediates coronary vasodilation. J Pharmacol Exp Ther, in press.
8. 2A adenosine receptors on sleep-waking patterns in rats. Drug Dev Res 37:65-72.
9. Bona E, Åden U, Gilland G, Fredholm BB, Hagberg H (1997): Neonatal cerebral hypoxia-ischemia: The effect of adenosine receptor antagonists. Neuropharmacology 36:1327-1338.
10. 2 receptors? Pharmacol Ther 71:325-335.
11. 2 adenosine receptor antagonist 8FB-PTR an 8-substituted pyrazolo-triazolo-pyrimidine, on in vitro functional models. Br J Pharmacol 112:659-665.
12. 3H]-SCH 58261. J Pharmacol Exp Ther 298:1209-1214.
13. 3H]-SCH 58261. Br J Pharmacol 121:353-360.
14. Fein T, Schulze Bär J, Schwabe U (1994): Purification and characterization of an adenotin-like adenosine binding protein from human platelets. Naunyn-Schmiedeberg's Arch Pharmacol 349:374-380.
15. 2A receptor antagonism potentiates 1-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats. Eur J Pharmacol 321:143-147.
16. 2B adenosine receptor subtypes. Biochem Pharmacol, in press.
17. Ferrè S, Fredholm BB, Morelli M, Popoli P, Fuxe K (1997): Adenosine-dopamine receptor-receptor interaction as an integrative mechanism in the basal ganglia. Trends Neurosci 20:482-487.
18. Fredholm BB (1995): Adenosine, adenosine receptors and the actions of caffeine. Pharmacol Toxicol 76:93-101.
19. Fredholm BB, Abbracchio MP, Burnstock G, Daly JW, Harden TK, Jacobson KA, Leff P, Williams M (1994): Nomenclature and classification of purinoceptors. Pharmacol Rev 46:143-156.
20. 2A receptor antagonist, is a useful ligand in autoradiographic studies. J Neurochem 70:1210-1216.
21. 2 receptor antagonist, reduces cerebral ischemic injury in the mongolian gerbil. Life Sci 55:61-65.
22. 2 adenosine receptor antagonists. Eur J Med Chem 28:569-576.
23. 3 receptor subtype. J Med Chem 39:4142-4148.
24. Jacobson MA (1995): Molecular biology of adenosine receptors. In Belardinelli L, Pelleg A (eds): Adenosine and Adenine Nucleotides: From Molecular Biology to Integrative Physiology. Boston: Kluwer, pp 5-14.
25. 1 receptor-mediated effects on c-fos expression. J Neuroscience 17:8038-8048.
26. 2A receptor. Nature 388:674-678.
27. 3H]CGS 21680 in the rat brain. Naunyn-Schmiedeberg's Arch Pharmacol 354:539-541.
28. Mally J, Stone TW (1996): Potential role of adenosine antagonist therapy in pathological tremor disorders. Pharmacol Ther 72:243-250.
29. 2A adenosine receptor antagonist, SCH 58261, in the rat. J Pharmacol Exp Ther, in press.
30. Morgan JI, Curran TE (1995): Proto-oncogenes. Beyond second messengers. In Bloom FE, Kupfer DJ (eds): Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press, pp 631-642.
31. Müller CE, Stein B (1996): Adenosine receptor antagonists: Structures and potential therapeutic applications. Curr Pharm Des 2:501-530.
32. 2A receptors. Trends Pharmacol Sci 17:364-372.
33. 2A receptors. Drug Dev Res 39:450-460.
34. 2A receptors and neuroprotection. Ann NY Acad Sci 825:30-48.
35. 2A adenosine receptor antagonists on cerebral ischemic injury in the gerbil. Brain Res 705:79-84.
36. 2A adenosine receptors positively modulates turning behaviour and c-fos expression induced by D1 agonists in Dopamine-denervated rats. Eur J Neurosci 8:1176-1181.
37. Porkka-Heinskanen T, Strecker RE, Thakkar M, Bjørkum AA, Greene RW, McCarley RW (1997): Adenosine: A mediator of the sleep-inducing effects of prolonged wakefulness. Science 276:1265-1268.
38. 2A receptor antagonists as new agents for the treatment of Parkinsons disease. Trends Pharmacol Sci 18:338-344.
39. 2A receptors underlies the behavioural activating effect of caffeine and is associated with reduced expression of mRNA for NGFI-A and NGFI-B in caudate-putamen and nucleus accumbens. Neuroscience 79:753-764.
40. 3H]CGS 21680 binding. Br J Pharmacol 117:1693-1701.
41. 3H]-SCH 58261 binding. Br J Pharmacol 122:386-392.
42. 2A receptors in human neutrophil membranes. Br J Pharmacol, in press.
43. Williams M, Francis J, Ghai G, Braunwlder A, Psychoyos S, Stone GA, Cash WD (1987): Biochemical characterization of the triazoloquinazoline, CGS 15943, a novel non-xanthine adenosine antagonist. J Pharmacol Exp Ther 241:415-420.
44. Williams M, Wright S, Lloyd GK (1997): Improved therapies for Parkinson's disease: Life beyond dopamine D2/D3 receptor agonists. Trends Pharmacol Sci 18:307-310.
45. 2A adenosine receptor antagonist. J Pharmacol Exp Ther 276:398-404.
46. 2A adenosine receptor antagonist, to rat striatal membranes. Br J Pharmacol 117:1381-1386.